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ABSTRACT 
The majority of persons currently treated for chronic hepatitis B require long-term or lifelong therapy. 
New inhibitors of hepatitis B virus entry, replication, assembly or secretion, and immune-modulatory 
therapies are in development.  The introduction of these novel compounds for chronic hepatitis B 
necessitates a standardized appraisal of the efficacy and safety of these treatments, and definitions of 
new or additional endpoints to inform clinical trials. To move the field forward, and to expedite the 
pathway from discovery to regulatory approval, a workshop with key stake holders was held in 
September 2016 to develop a consensus on treatment endpoints to guide the design of clinical trials 
aimed at hepatitis B cure. The consensus reached was that a complete sterilizing cure i.e. viral 
eradication from the host is unlikely to be feasible. Instead, a functional cure characterized by sustained 
loss of HBsAg with or without anti-HBs seroconversion, which is associated with improved clinical 
outcomes, in a higher proportion of patients than is currently achieved with existing treatments is a 
feasible goal.  Development of standardized assays for novel biomarkers towards better defining HBV 
cure should occur in parallel with development of novel antiviral and immune modulatory therapies 
such that approval of new treatments can be linked to the approval of new diagnostic assays used to 
measure efficacy or to predict response. Combination of antiviral and immune modulatory therapies will 
likely be needed to achieve functional HBV cure. Limited proof-of-concept monotherapy studies to 
evaluate safety and antiviral activity should be conducted prior to proceeding to combination therapies.  
The safety of any new curative therapies will be paramount given the excellent safety of currently 
approved nucleos(t)ide analogues. 
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INTRODUCTION  
The advent of several novel antiviral and immune modulatory therapies for chronic hepatitis B 
now necessitates a standardized appraisal of the efficacy and safety of these therapies, and definitions 
of new or additional endpoints to inform clinical trials. To move the field forward, and to expedite the 
pathway from discovery to regulatory approval, the American Association for the Study of Liver Diseases 
and the European Association for the Study of the Liver jointly organized a Hepatitis B Treatment 
Endpoints Workshop on September 8-9, 2016 in Alexandria, Virginia. The primary goal of this workshop 
was to assemble key stake holders from regulatory agencies (United States Food and Drug 
Administration (U.S. FDA) and European Medicines Agency), biopharmaceutical and biotechnology 
companies engaged in development of diagnostic tests and therapeutic agents for hepatitis B, and 
academia, in order to develop a consensus on treatment endpoints to guide the design of clinical trials 
aimed at hepatitis B cure.  
Sixty-six (33%) of 202 participants completed a pre-meeting survey, including 4 from regulatory 
agencies, 31 from industry, 28 from academia, and 3 from other healthcare sectors. During the 
workshop, experts reviewed the natural history of chronic hepatitis B virus (HBV) infection, efficacy of 
currently approved treatments, potential antiviral targets and approaches to restore immune 
responsiveness to HBV, and pre-clinical and early phase clinical trial data on novel antiviral and immune 
modulatory therapies for chronic HBV. The workshop concluded with a session on definition of HBV 
cure; efficacy endpoints, safety assessments, target populations and design of clinical trials; and 
diagnostic assays needed to support development of curative therapies. These topics were further 
discussed during a closed session involving 23 experts (including the four authors) representing all 
constituent groups. This report summarizes the discussions and consensus opinions of the 2-day 
meeting.  
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DEFINTION OF HBV CURE 
The goal of developing new therapies is to achieve HBV cure, i.e. elimination of HBV, thereby 
allowing treatment to be stopped with no risk of virological relapse and no risk of liver disease 
progression. However, a true cure may not be feasible because HBV DNA is integrated into the host 
genome; even among persons who recovered from acute HBV, viral covalently closed circular DNA 
(cccDNA) can be detected in the liver explaining the reactivation of HBV replication when these 
“recovered” persons are profoundly immunosuppressed. However, the observation that hepatitis B 
surface antigen (HBsAg) may become undetectable in serum after clinical recovery from acute hepatitis 
B, spontaneously during the course of chronic HBV infection, and during or after nucleosid(t)e analogue 
(NA) or interferon (IFN) therapy, despite the likelihood of persistent integrated HBV genomes, argues for 
the feasibility of achieving undetectable levels of HBsAg.  
 
 A key objective of the meeting was to establish a definition of cure. Three definitions of HBV 
cure were proposed at this meeting: (1) Complete sterilizing cure with undetectable HBsAg in serum and 
eradication of HBV DNA including intrahepatic cccDNA and integrated HBV DNA. (2) Functional cure with 
sustained, undetectable HBsAg and HBV DNA in serum with or without seroconversion to hepatitis B 
surface antibody (anti-HBs) after completion of a finite course of treatment, resolution of residual liver 
injury and a decrease in risk of HCC over time. Several levels of functional cure including complete shut-
down of cccDNA transcription, elimination of cccDNA, complete resolution of liver damage, and 
elimination of risk of HCC were discussed. (3) Partial cure with detectable HBsAg but persistently 
undetectable HBV DNA in serum after completion of a finite course of treatment.  
The vast majority (87.9%) of survey respondents selected functional cure (sustained HBsAg loss) 
as the goal for new HBV therapies. This selection was endorsed by other participants and the expert 
panel as a feasible goal. In addition, functional cure offers several other advantages: it is easy to assess 
Page 5 of 48
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
6 
 
and tests are widely available, it is associated with improved clinical outcomes and lower rates of 
disease reactivation and once achieved, there is no further requirement for therapy. 
There was less consensus regarding the necessity of achieving anti-HBs seroconversion because 
it is unclear whether durability of HBsAg loss and clinical benefits of HBsAg loss are dependent on 
development of anti-HBs. Importantly, few of the participants believed elimination of cccDNA was a 
mandatory criterion for functional cure and less than half required cccDNA be rendered transcriptionally 
inactive reflecting uncertainties whether new therapies in development can silence or clear cccDNA, as 
well as pragmatic difficulties in measuring cccDNA.  
Some members of the expert panel considered partial cure (sustained suppression of HBV 
replication off treatment but persistent presence of HBsAg) an acceptable intermediary step toward 
functional cure because partial cure is more achievable in the short-term, has been shown to lead to a 
reduction in clinical outcomes,
1
 and could expedite drug development. 
 
NATURAL HISTORY OF CHRONIC HBV INFECTION  
 
The natural history of chronic HBV infection is variable and dependent on a complex interplay 
between the host immune response and the virus.  Chronic HBV infection comprises four phases defined 
by three clinical parameters: serum alanine aminotransferase (ALT) concentrations, serum HBV DNA 
levels and hepatitis B e antigen (HBeAg) status (Figure 1). The first phase is characterized by the 
presence of HBeAg and high serum HBV DNA but normal ALT levels. It has been called the “immune 
tolerant” phase though recent studies have challenged the concept of immune tolerance.  HBV-specific 
T cell responses have been observed in patients in the immune tolerant phase with similar frequency as 
in patients in the immune active phase. This finding has led some to propose that the immune response 
is better characterized as low inflammatory during the immune tolerant phase (as opposed to 
inflammatory during the immune active phase).
2-4
 The immune tolerant phase is followed by the 
“HBeAg-positive immune active” phase, when ALT levels become elevated.   After varying intervals, 
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seroconversion from HBeAg to HBe antibody (anti-HBe) occurs and a majority of patients transition to 
the “inactive carrier” phase during which ALT levels return to normal and serum HBV DNA levels are low 
or undetectable.  In some patients, serum HBV DNA and ALT levels become elevated again, after years 
or decades. These patients are considered to be in the “HBeAg-negative immune active” phase which is 
characterized by fluctuating HBV DNA and ALT levels. The annual incidence of HBeAg-negative immune 
active hepatitis among inactive carriers is estimated to be 0.37%.
5
 Some patients do not fit into any of 
these conventional phases. Serum HBsAg levels are highest during the immune tolerant phase and 
lowest during the inactive carrier phase. Consequently, quantification of serum HBsAg levels may help in 
determining the phase of infection particularly for HBeAg-negative persons
6
 and to predict the risk of 
disease progression and hepatocellular carcinoma (HCC) in HBeAg-negative patients with low viremia 
(HBV DNA <2000 IU/mL).
7
  Because phases of chronic HBV infection are defined based on clinical and not 
immunologic measures, the recent European Association for the Study of Liver Diseases proposed to 
describe these four phases as phases 1, 2, 3, and 4 [ref]. Patients in phases 1 and 2 would be HBeAg-
positive and those in phases 3 and 4 would be HBeAg-negative and those with inactive disease (phases 1 
and 3) would be considered to have chronic infection while those with active disease (phases 2 and 4) 
would be considered to have chronic hepatitis.  
Some patients spontaneously clear HBsAg but this event is rare, occurring at a rate of 0.5 to 1% 
per year. These patients remain positive for hepatitis B core antibody and some may develop anti-HBs. 
The majority of patients who clear HBsAg have undetectable HBV DNA in serum but HBV DNA persists in 
the serum in some, and in the liver in all patients. These patients are considered to have occult HBV 
infection. While the risk of cirrhosis and end-stage liver disease is greatly diminished, the risk of HCC 
after HBsAg loss remains substantial particularly if HBsAg loss occurred after the age of 50 or after 
development of cirrhosis.
8-10
 Importantly, HBV can be reactivated upon immunosuppression suggesting 
that eradication of HBV from the host is rarely achieved.
11
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Identifying individuals at greatest risk for development of cirrhosis and HCC is an important goal 
in the management of chronic HBV infection. Recent studies have highlighted the importance of viral 
load in predicting risk of cirrhosis and HCC.
12,13
 However, many other host (sex, age, family history of 
HCC, obesity, diabetes), viral (HBV genotype and variants, coinfection with other viruses: hepatitis C, 
hepatitis D, HIV), and environmental (alcohol, smoking, carcinogens) factors contribute to liver disease 
progression.  
Several risk models have been developed to predict risk of HCC.
14-18
 Most of these models were 
derived from data in Asians. The applicability of these models to all racial/ethnic groups and HBV 
genotypes, patients with or without cirrhosis, and untreated patients as well as those receiving antiviral 
therapy has not been confirmed. Cirrhosis is the major risk factor for HCC. In the past decade, non-
invasive assessment – serum marker panels and liver stiffness measurements - have largely replaced 
liver biopsies in staging of liver fibrosis. These non-invasive tests have also been shown to predict 
survival and HCC in patients with chronic HBV infection because they have high accuracy in diagnosing 
cirrhosis.
19-23
  
 
CURRENT STATUS OF HBV TREATMENT  
Goals of treatment and efficacy assessment 
The goals of HBV therapy are to prevent the development of cirrhosis, hepatic decompensation, 
HCC and death from HBV-related liver disease. The eventual clinical outcomes of chronic hepatitis B, 
requires years if not decades of surveillance; therefore, biochemical (normalization of ALT), virological 
(suppression of serum HBV DNA), serological (HBeAg and/or HBsAg loss with or without seroconversion 
to anti-HBe and anti-HBs) and histological (decrease in hepatic necroinflammation with or without 
improvement in fibrosis) markers have been used as surrogates for clinical outcomes: cirrhosis, hepatic 
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decompensation, HCC and HBV-related mortality and to assess indications for treatment, response and 
prognosis.  The durability of responses after treatment discontinuation is variable.   
 
Indications for treatment 
The decision to treat is based upon clinical assessment of the risk of disease progression which is 
related to phase of disease. This risk assessment is based primarily on HBV DNA and ALT levels and the 
stage of disease, as assessed by liver biopsy or non-invasive staging of hepatic fibrosis.  Current 
guidelines recommend treatment for patients with cirrhosis or decompensated liver disease and, for 
patients without cirrhosis, evidence of modest to high viremia and biochemical or histological evidence 
of hepatic necro-inflammation. 
24-26
 Continued high levels of HBV replication together with hepatic 
inflammation increases the risk of cirrhosis and HCC; however, currently available therapies have lower 
efficacy in patients in the immune tolerant phase and treatment is not recommended for these patients. 
27,28
 
 
Approved therapies 
Two classes of antiviral therapies have been approved for treatment of hepatitis B: IFNs and 
NAs. An advantage of IFN is it results in higher rates of HBeAg and HBsAg loss (particularly in patients 
with genotype A infection) compared to NAs. Pegylated IFN administered for 48-52 weeks results in 
HBeAg seroconversion in 24% to 27% and HBsAg loss in 3% to 7% of patients compared to 12% to 22% 
HBeAg loss and 0% to 3% HBsAg loss after the same duration of NA therapy. 
29
 Response to IFN is also 
more durable and HBeAg and HBsAg loss may occur after cessation of treatment, while virological 
relapse, even after HBV DNA has become undetectable, is frequent after cessation of NA. 
30
 However, 
IFN is less effective at suppressing viral replication compared to NAs, requires parenteral administration, 
is associated with numerous adverse effects, and is contraindicated in patients with decompensated 
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cirrhosis or severe exacerbations of hepatitis and those with autoimmune or psychiatric illnesses. NAs 
are administered orally and have negligible adverse effects. The recommended first-line NAs – entecavir 
and tenofovir have low risk of drug resistance but the requirement for indefinite therapy in the majority 
increases the cost and risk of non-adherence and adverse effects.  
Various combinations of IFN and NA have been evaluated, but most studies have not shown an 
added benefit compared to monotherapy. A recent study showed that combination of pegylated IFN 
and tenofovir increased the rate of HBsAg loss to 9% at week 72 but the benefit was mainly observed in 
patients with genotype A.
31
 Therefore, there is an urgent need to develop new therapies for HBV that 
can result in durable suppression of HBV replication, and an ensuing decrease in hepatic inflammation 
and fibrosis after a finite course of therapy.  In addition, more research is needed to identify which 
patients can safely stop therapy.  Importantly HBsAg loss at an older age and after the development of 
cirrhosis does not eliminate the risk of HCC; however, the benefit of further treatment for preventing 
HCC has not been proven. 
32
 Treatment that can result in a functional cure at an earlier stage of disease 
might have a greater impact in preventing HCC.  
 
Lack of impact of NA on covalently closed circular DNA (cccDNA) 
A major hurdle to HBV “cure” is the presence of cccDNA in the hepatocyte nucleus in a non-
integrated form or episome. cccDNA serves as the template for transcription of all viral RNAs including 
pregenomic RNA and thus plays a key role in the viral lifecycle. There are two sources of cccDNA: 
incoming virions and re-cycling of encapsidated DNA from the hepatocyte cytoplasm. The half-life of 
cccDNA is long thus explaining why it is difficult to cure HBV infection and why HBV can reactivate either 
spontaneously or following immune suppression, many years after clearance of HBsAg. Chain 
terminating NAs block the reverse transcription of pregenomic RNA (pgRNA) to HBV DNA but they have 
marginal effect on cccDNA production, stability or transcription. Continued transcription from cccDNA 
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and integrated viral genomes may explain the relatively minor decrease in serum HBsAg levels during NA 
therapy despite undetectable serum HBV DNA levels.
33
 Unfortunately, current assays for circulating 
HBsAg cannot distinguish the transcription of HBsAg  from cccDNA versus integrated HBV DNA.  
 
Impact of antiviral treatment on clinical outcomes 
Most but not all long-term follow-up studies and meta-analyses indicate that IFN and NA 
treatment decrease the risk of HCC and liver-related mortality.
34
 A landmark randomized controlled trial 
showed that the first-generation NA, lamivudine, decreased the risk of disease progression and HCC in 
patients with advanced fibrosis or cirrhosis and high viremia.
1
 Several studies have shown that 
maintained viral suppression during NA therapy is associated with regression of fibrosis and reversal of 
cirrhosis and reduction in rates of hepatic decompensation.
35,36
 The risk of HCC is also diminished 
although not eliminated, making it the only major complication during NA treatment. The observed 
reduction in the incidence of HCC appears to be more evident in persons with cirrhosis and after several 
years of continued treatment.
34
  
 
NOVEL ANTIVIRAL THERAPIES  
 
Recent major scientific discoveries have allowed a better understanding of the HBV lifecycle, 
including the identification of the cellular receptor for HBV entry, information on the key nuclear 
enzymes involved in cccDNA formation and on its epigenetic control, the observation of partial cccDNA 
degradation induced by IFN or NF-κB signaling pathways, and identification of the role of the HBx 
protein in HBV transcription. Improved cellular and animal models have also enhanced the in vitro and 
in vivo assessment of the antiviral activity of novel compounds, and their potential toxicity. These major 
advances in hepatitis B basic research have paved the way for the identification of multiple new 
therapeutic targets (Figure 2), essential progress toward a “cure” for hepatitis B. A list of novel antiviral 
therapies tested in clinical trials is provided in supplementary table 1. 
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HBV entry inhibitors 
The pathway by which HBV enters hepatocytes involves virus attachment to Heparan Sulfate 
Proteoglycans, allowing the binding of HBV preS1 to human sodium taurocholate cotransporting 
polypeptide (hNTCP), followed by membrane fusion and nucleocapsid release in the cytoplasm of 
infected cells.  
Entry inhibitors can be classified according to their modes of action: (1) Neutralizing antibodies 
target the antigenic loop of HBV S-domain or N-terminal epitopes in the preS1-domain. These antibodies 
are highly specific but require parenteral administration and large quantities of antibodies are necessary 
to neutralize circulating subviral envelope particles. (2) Attachment inhibitors are negatively or 
positively charged drugs that bind the virus (e.g. heparin) or cellular heparan sulphate proteoglycans 
(e.g. poly-Lysin). They are efficient but not specific. (3) Substrates of NTCP including conjugated bile salts 
(e.g. taurocholate, or ezetimibe) or other small molecules that are transported by NTCP; requirement for 
high concentrations and short half-time at the receptor limit their clinical application. (4) Irreversible 
NTCP inhibitors: Myrcludex B (myristolated pre-S1 peptide), Cyclosporin A and derivatives are allosteric 
inhibitors of NTCP. They irreversibly block receptor function at non-saturating concentrations and have 
long half-time at the receptor but they can block transport of bile salts and other NTCP substrates at 
higher concentrations. 
Entry inhibitors may prevent de novo cccDNA formation in non-infected hepatocytes, and might 
be more effective in preventing mother-to-child transmission or reinfection after liver transplantation 
than in eliminating HBV in chronically-infected persons. 
Clinical trials of Myrcludex B with or without pegylated IFN in chronic HBV and chronic HDV 
infection are underway.
37,38
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Targeting covalently closed circular DNA 
Damage and destruction 
A number of studies demonstrate that it might be possible to target cccDNA despite its location 
in the protected sanctuary of the hepatocyte nucleus. Studies in cultured hepatocytes showed that 
several cytokines (IFN-α, lymphotoxin-β receptor agonists, IFN-γ and tumor necrosis factor-α) can 
modulate pathways leading to the up-regulation of APOBEC3A/B deaminases, which in turn induced 
non-hepatotoxic degradation of cccDNA.  However, only partial degradation was achieved in these 
tissue culture studies.
39
 DNA cleavage enzymes, including homing endonucleases or meganucleases, 
zinc-finger nucleases, TAL effector nucleases, and CRISPR-associated (cas) nucleases, specifically 
targeting cccDNA are being explored in experimental models.
40
 Some studies suggest that editing of HBV 
DNA by CRISPR-associated (cas) nuclease cleavage is more efficient than APOBEC-mediated cytosine 
deamination following treatment of infected cells with IFN.
41
 Efficient delivery of these gene editing 
approaches to HBV-infected hepatocytes without unintended off-target effects will need to be 
addressed before they can be tested in clinical trials. 
 
Functional silencing 
Viral cccDNA is organized into a chromatin-like structure and is subject to epigenetic 
regulation.
42
 Epigenome modifiers can potentially block cccDNA transcriptional activity and shut-down 
viral protein expression; however, if not specific, they may induce harmful effects on host cells. Some 
cytokines including IFN-α have been shown to decrease cccDNA transcription via epigenetic 
modifications in preclinical models.
43
 HBx has been shown to be required for cccDNA transcription and 
viral replication via degradation of the Smc5/6 restriction factor; thus, HBx may be an attractive viral 
target to silence not only cccDNA transcription
44
 but also several other HBx-dependent virus-related 
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cellular interactions. Current assays to detect cccDNA lack specificity and a standardized method to 
measure cccDNA or cccDNA transcription is needed. 
 
Targeting viral transcripts 
The use of RNA interference to inhibit replication of HBV has been extensively evaluated in vitro 
and validated in animal models. Small interfering RNA (siRNA) can be designed to target any viral 
transcript and induce their degradation by the RISC/Ago2 complex resulting in gene silencing. The 
potential limitations are the need for intravenous administration, the risk of off-target binding, the 
potential toxicity of the vehicle, and the risk of immune activation by pattern recognition receptors. 
Three siRNA formulations with different modes of delivery are under pre-clinical evaluation and/or early 
phase clinical trial. Preliminary results of a phase 2 trial showed a single dose of ARC-520 in combination 
with entecavir resulted in profound and durable decrease in serum HBV DNA in both HBeAg-positive and 
HBeAg-negative patients and decrease in HBsAg level in HBeAg-positive but not in HBeAg-negative 
patients.
45,46
 The siRNAs were designed to target the co-termini of all transcripts from cccDNA and the 
lack of effect on HBsAg level in HBeAg-negative patients was postulated to be due to altered viral 
transcript sequences derived from integrated HBV DNA. Further studies are needed to determine 
whether the decline in HBsAg production alone might be sufficient to restore HBV-specific T cell 
response, or if addition of other antiviral or immune modulatory therapies is needed.  
Antisense oligonucleotides targeting viral transcripts can block viral protein expression via steric 
blockade of protein translation and/or RNA degradation by RNAseH cleavage. In vitro and in vivo pre-
clinical evaluation have shown their potential to inhibit viral replication and decrease viral antigen load 
but optimal delivery remains a challenge.  
 
Nucleocapsid assembly and Pregenomic RNA (pgRNA) packaging 
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Nucleocapsid formation and packaging of the pregenomic RNA (the template for viral 
replication) are critical steps of the viral lifecycle. Therefore, developing inhibitors or modulators of this 
process are attractive therapeutic approaches.  The HBV core protein is involved in many aspects of the 
viral lifecycle including transport of viral genome to the nucleus, uncoating to release relaxed circular 
DNA (rcDNA) in the nucleus, packaging of polymerase protein and pgRNA, capsid assembly, modulation 
of reverse transcription, and interaction with envelope proteins for virus assembly. It may have 
additional functions including modulation of cccDNA chromatin and stability, nuclear export of viral 
RNAs and modulation of innate immunity.  
The HBV precore/core protein has recently emerged as a promising direct antiviral target. With 
the knowledge of the 3-dimensional structure of the core protein, several classes of non-nucleoside 
small molecules called core protein assembly modulators have been developed, including 
phenylpropenamide and heteroaryldihydropyrimidine derivatives. These molecules can strengthen 
protein-protein interaction, inhibit pgRNA encapsidation, and block plus strand DNA synthesis.
47,48
 
Results of the first dose ranging phase 1b study of NVR3-778 showed a decline in serum HBV DNA, HBV 
RNA and HBsAg, with more pronounced effect when combined with pegylated IFN.
49
  
 
Targeting HBsAg 
Strategies inhibiting viral gene expression either through cccDNA transcription or viral mRNA 
translation can decrease serum HBsAg levels. Owing to the large amount of circulating HBsAg in persons 
with chronic HBV infection, monoclonal antibodies aimed at neutralizing and/or depleting HBsAg from 
the bloodstream are unlikely to be effective unless used in combination with other approaches.  
Nucleic acid polymers have been shown to decrease secreted HBsAg, through as yet unknown 
mechanisms. Clinical trials of REP 2055 and REP 2139 used in monotherapy followed by combination 
with pegylated IFN or thymosin alpha-1 induced a marked decline in circulating HBsAg levels and viremia 
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and anti-HBs seroconversion in some patients.
50
 Similar results were observed in pilot studies of 
tenofovir and pegylated IFN in combination with REP 2139 or REP 2165.
51
 These results need to be 
replicated in larger studies and the potential for cytotoxicity resulting from intracellular retention of 
HBsAg must be resolved. 
 
IMMUNE RESPONSE TO HBV AND IMPLICATIONS FOR IMMUNE MODULATORY THERAPIES 
 
An orchestrated innate and adaptive immune response is necessary to sense and control HBV 
infection. The induction of innate pro-inflammatory responses and cytokine activation are weak in 
chronic HBV infection. 
52
  IFN-γ production from NK cells is detectable in acute hepatitis, but deficient in 
chronic hepatitis. HBV-specific T cells necessary for HBV control (and may also play a role in hepatic 
inflammation) are dysfunctional and may be depleted or deleted in chronic HBV.
53,54
 Their exhausted 
phenotype has been attributed to persistent antigen exposure and increased expression of T cell 
inhibitory responses, 
3,52,55
 providing the basis for the focus on reducing HBsAg production. B cell 
dysfunction in chronic hepatitis B is less well characterized though the high rate of HBV reactivation in 
patients receiving anti-CD20 suggests that B cells play a role in immune control of chronic HBV.  
Accordingly, several potential target mechanisms for immune modulation to engender or restore HBV-
specific immune responses in conjunction with profound inhibition of HBV replication and HBsAg 
production to attain immunological control have been suggested (Figure 3).  The main concerns of 
immune modulatory therapy are the induction of uncontrolled hepatitis flares or autoimmunity.  
 
Interferons 
IFN-α have been used to treat chronic HBV and chronic HDV. IFN-α induces expression of IFN 
sensitive genes encoding intracellular or secreted effector proteins with antiviral properties.  Recent 
studies showed that IFN-α also inhibits pgRNA encapsidation, enhances cccDNA degradation, and exerts 
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epigenetic modification of cccDNA transcription.
39,56
 Response to IFN-α (HBeAg seroconversion) is 
durable in >70% of patients.
57,58
 Understanding the mechanisms for IFN non-responsiveness and the 
higher rates of response in genotype A infection could lead to new targets for antiviral and/or immune 
modulatory therapies. 
 
Pathogen recognition receptors  
Pathogen recognition receptors are an important gateway to sensing by the innate immune 
system. Pharmacological activation of the intrahepatic innate immune response with toll-like receptors 
7, 8, or 9 have been studied. GS-9620, an oral agonist of toll-like receptor 7, induced a decline in serum 
HBV DNA and HBsAg levels as well as hepatic HBV DNA in HBV-infected chimpanzees.
59
 Similar effects 
were also observed in woodchucks
60
 but not in humans.
61,62
 The discrepancies between results in animal 
models and humans highlight the importance of testing new therapies in humans at an early stage in 
drug development.   
 
Stimulator of interferon genes (STING) agonists 
Stimulator of interferon gene is the adapter protein of multiple cytoplasmic DNA receptors and 
a pathogen recognition receptor recognizing bacterial second messenger,  and may be a potential target 
of pharmacologic activation of the innate immune response.
63
 Stimulator of interferon gene agonists can 
also be used as adjuvants to therapeutic vaccination. Retinoic-acid-inducible protein 1 had been shown 
not only to induce IFN and cytokine production but also inhibit HBV replication through sensing of the 
epsilon structure of pgRNA.
64
 SB 9200, an oral prodrug of the dinucleotide SB 9000, is thought to 
activate retinoic-acid-inducible protein 1 and nucleotide-binding oligomerization domain-containing 
protein 2, resulting in IFN-mediated antiviral immune responses in virus-infected cells, and decreased 
serum woodchuck hepatitis virus DNA and surface antigen levels.
65
 Clinical trials are ongoing.  
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Check point modulation 
The lack of a T-cell mediated response in chronic HBV is partly due to overexpression of co-
inhibitory receptors including programmed cell death (PD-1), cytotoxic T lymphocyte associated antigen-
4 lymphocyte activation gene and mucin domain to impair T cell effector function. T cell function may 
also be impaired by immunosuppressive cytokines including IL-10.  Recent cancer therapies have 
indicated the potential of blockade of these co-inhibitory receptors with antibodies.  Such inhibition may 
reverse immune dysfunction in hepatitis B as demonstrated in studies in woodchucks and ex vivo studies 
in humans.
4,66-68
 The main concerns of this approach are induction of uncontrolled hepatitis flares and 
autoimmunity which can lead to fatal organ damage.
69
  
 
Therapeutic vaccine 
The goal of therapeutic vaccination is to stimulate or boost the host immune response to 
restore immune control resulting in sustained suppression of HBV replication and ultimately HBsAg loss. 
Therapeutic vaccination strategies including conventional HBsAg vaccine +/- potent adjuvants, T-cell 
vaccine, immune complexes of HBsAg and human anti-HBs, apoptotic cells that express HBV antigens, 
DNA vaccines or viral vectors expressing HBV proteins have been evaluated with limited success. 
Patients with high viral loads may be less responsive and patients with cirrhosis may be at higher risk for 
immune-mediated hepatitis flares. Pre-treatment with NAs to suppress HBV replication may enhance 
HBV-specific T cell response and prevent flares.  GS-4774, a heat-inactivated yeast-based vaccine 
expressing HBV S/C/X fusion protein induced HBV-specific T cell responses in healthy volunteers but 
HBsAg decline and HBsAg loss was not observed in chronic hepatitis B patients virally suppressed on NA 
as well as those who were NA-naive .
70-72
 A list of therapeutic vaccines tested in clinical trials is provided 
in supplementary table 1.  
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COMBINATION OF ANTIVIRAL AND IMMUNE MODULATORY THERAPIES 
Combinations of antiviral therapy targeting multiple steps in the HBV lifecycle to suppress viral 
replication and viral antigen production and immune modulatory therapy to restore immune response 
to HBV will likely be needed to achieve the goal of HBV “cure” but which specific combination of agents 
will be needed is not certain since most antiviral or immune modulatory drugs in clinical evaluation are 
entering either Phase 1b or Phase 2 trials at this time. The possibility that HBV-specific T cell function 
can be partially restored has been demonstrated in patients with chronic HBV who had spontaneous or 
antiviral (IFN or NA)-mediated HBeAg or HBsAg loss.
73,74
 With the availability of novel approaches such 
as siRNA or combination of antiviral agents targeting different steps in HBV lifecycle, marked reduction 
and even shut-down of HBsAg production may be achieved in a higher proportion of patients. The 
reduction in antigen load might facilitate the restoration of HBV-specific T-cell responses. Historically, 
immune modulatory therapies have focused on patients in the immune active phase but recent studies 
suggest that patients in the “immune tolerant or high-replication non-inflammatory” phase should also 
be considered, as HBV-specific T cells are present in this phase of disease.
3,75
 The ability to “cure” 
hepatitis B at earlier stages of liver disease would theoretically have a greater impact on reducing risk of 
HCC. 
 
CLINICAL TRIALS AIMED AT HBV CURE  
Efficacy endpoints for clinical trials 
Initial trials of IFN and NA used biochemical, virological, serological and histological endpoints to 
assess efficacy while more recent trials have focused on virological and serological endpoints because 
these endpoints have been shown to correlate with improved clinical outcomes.
35,76-78
 The use of a 
biochemical endpoint is problematic because of the lack of a standardized definition of normal ALT.  
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Furthermore, with increasing prevalence of obesity and non-alcoholic fatty liver disease, failure to 
normalize ALT may not necessarily indicate ongoing liver inflammation induced by HBV. Indeed, phase 3 
clinical trials of NA have consistently found a lower percent of patients achieving a biochemical versus a 
virological response. Non-invasive assessments of liver fibrosis have replaced liver biopsies in assessing 
liver disease in clinical practice and a histological endpoint would no longer be practical or necessary for 
assessing functional cure. However, liver biopsies may be required in proof-of-concept studies to 
confirm a novel mode of action and/or to validate noninvasive surrogate markers of antiviral activity.  
For both antiviral and immune modulatory therapy trials, survey respondents ranked 
suppression of serum HBV DNA to undetectable and loss of HBsAg as the most important primary 
efficacy endpoint for phase 2 and phase 3 trials, respectively and the expert panel agreed. The 
difference in ranking of primary efficacy endpoint for phase 2 vs. phase 3 trials reflects a desire to have 
an earlier read-out in phase 2 trials and the potential difficulty in achieving HBsAg loss after shorter 
treatment. HBV DNA suppression will not be an appropriate endpoint for trials enrolling patients who 
are virally suppressed on NA. Decline in serum HBsAg level has been used as an endpoint in some trials 
but there is no consensus whether the kinetics of decline in HBsAg level can predict ultimate HBsAg loss.  
There was general consensus (~65%) that the most appropriate time to assess the primary 
efficacy endpoint for phase 3 trials of novel antiviral or immune modulatory therapies should be month 
6 post-treatment. The choice reflected the intent to achieve a durable response (“cure”) after a finite 
course of treatment. There was less consensus on the optimal time for assessing efficacy in phase 2 
trials with the responses divided between month 6 on-treatment versus month 6 post-treatment.  The 
expert panel indicated that the most appropriate time to assess efficacy endpoints may depend on 
mechanism of action and half-life of the drug. For example, drugs that inhibit reverse transcription of 
HBV pregenomic RNA to HBV DNA are expected to result in rapid decline in serum HBV DNA levels while 
drugs aimed at restoring immune response may take longer to have any measurable effects on viral 
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load. The expert panel also emphasized the need for long-term follow-up to confirm durability of 
responses and impact on clinical outcomes.  
 
Diagnostic assays for new markers to determine therapeutic efficacy 
There was consensus on the need for standardized assays to provide mechanistic insights into 
the effects of novel antiviral or immune modulatory agents and to have new surrogate markers to assess 
HBV “cure” (Table 1).  
 
Serum HBsAg assays 
HBsAg loss was ranked as the most important efficacy endpoint for phase 3 trials of both novel 
antiviral and immune modulatory therapies. Some experts suggested the need for more sensitive HBsAg 
assays.  Others indicated that the persistence of low levels of HBsAg in serum may not stem from 
persistent cccDNA transcription but from integrated HBV DNA genomes.  Assays that can differentiate 
HBsAg originating from integrated HBV DNA versus cccDNA are required.  Failure to detect HBsAg in 
serum may not represent shut-down of HBsAg production as circulating HBsAg may be complexed to 
anti-HBs. HBV produces a surplus of empty envelope particles which can outnumber virions by >1,000-
fold. Assays that can differentiate surface proteins in virions versus subviral particles (large, middle 
versus small HBsAg proteins) would be informative.   
Serum HBsAg decline may be used as a surrogate to explore efficacy in early phase trials 
although its accuracy in predicting HBsAg loss has not been established. Quantitative HBsAg assays can 
also be used to categorize disease stage and to prognosticate. Several standardized quantitative HBsAg 
assays have been available in Europe and in Asia in the last decade and the consensus is that they will be 
essential tools for new drug development.  
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cccDNA quantification and transcriptional activity 
Many new antiviral agents in development aim to enhance elimination or degradation of 
cccDNA or to epigenetically modify cccDNA transcription. Assays that reliably measure concentrations of 
cccDNA and/or its transcriptional activity would directly assess efficacy of these agents and would be 
invaluable in proof-of-concept studies. Currently, there are no standardized assays for intrahepatic 
cccDNA.  However, there was consensus that an adequate sample of liver tissue would be necessary and 
appropriate measures to ensure specificity are needed particularly in the presence of abundant rcDNA.  
Assays for serum markers that are reliable surrogates of intrahepatic cccDNA would be desirable 
for clinical trials. Several studies have shown that serum HBsAg level correlates better with hepatic 
cccDNA than serum HBV DNA level suggesting that it is an indirect marker of cccDNA.
79,80
 However, 
while the correlation is satisfactory in HBeAg-positive patients it is suboptimal in HBeAg-negative 
patients.
79,81
 HBsAg can be translated from subviral RNAs transcribed from cccDNA or from integrated 
HBV DNA. It has been suggested that HBsAg is predominantly derived from cccDNA in HBeAg-positive 
patients while an increasing proportion is derived from integrated HBV DNA in HBeAg-negative persons. 
Recent studies suggest that serum HBV RNA and hepatitis B core-related antigen (HBcrAg) levels may be 
more reliable surrogates of hepatic cccDNA than HBsAg levels. 
 
Serum HBV RNA assays 
The vast majority of circulating HBV virions contain partially double stranded rcDNA; however, 
circulating “virions” containing HBV RNA had been reported.
82
 These RNA-containing “virions” are more 
abundant in patients receiving NA therapy probably because inhibition of reverse transcription of pgRNA 
by NA leads to accumulation of encapsidated pgRNA, some of which may be enveloped and secreted. 
Thus the detection of HBV RNA in serum in the absence of detectable serum HBV DNA in patients 
receiving NA therapy could infer ongoing cccDNA  transcription, and has been shown to be a predictor of 
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viral relapse after discontinuation of NA therapy.
83
 Assays for serum HBV RNA levels, particularly if they 
are specific for pgRNA, may provide a useful surrogate for transcriptionally active cccDNA. 
 
Serum hepatitis B core related antigen (HBcrAg) assays 
The HBV precore/core gene is translated into the core protein, precore/core precursor and 
HBeAg; these proteins can be collectively measured.  HBcrAg can assemble into defective, enveloped 
particles that that do not contain HBV RNA or HBV DNA. A core related antigen immunoassay measuring 
all these forms of precore/core gene expression has been developed.  Serum HBcrAg levels have been 
shown to correlate with hepatic HBV DNA and to predict viral relapse after discontinuation of NA 
therapy.
84
 Assays for serum HBcrAg levels may provide indirect evidence for transcriptionally active 
cccDNA.
85
  
 
Immune response to HBV 
Restoration of immune response to HBV is a key step towards HBV “cure”. Most immune 
modulatory therapies have focused on restoring T cell response. While markers of response to antiviral 
therapies can be used to evaluate immune modulatory therapies, standardized assays to measure 
improvement in specific immune responses to predict viral clearance would be informative in early 
phase drug development.  The development of standardized assays to assess restoration of immune 
responses to HBV will require consensus on the requisite assays, their methodology, sensitivity and 
specificity, their correct interpretation, reproducibility in different laboratories and cross-validation of 
the assays.   
 
Approval of HBV diagnostic assays 
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Development of standardized assays for surrogate endpoints for HBV cure should occur in 
parallel with development of novel antiviral and immune modulatory therapies to expedite research. 
During the closed session, the U.S. FDA and European Medicines Agency representatives proposed 
consideration of simultaneous testing of multiple intermediate secondary endpoints in all phase 2 and 3 
trials. The research assays must be standardized, and data and assay platforms shared to facilitate 
identification of the appropriate surrogate markers of efficacy. It is important that the approval of new 
treatments is linked to the development and approval of new diagnostic assays used to measure efficacy 
or to predict response.  
 
Assessment of safety and stop rules 
The remarkable safety profile of current NAs imposes a stringent requirement for the safety of 
new HBV therapies at all stages of the disease.  A unique concern in the development of hepatitis B 
therapies is the risk of severe hepatitis flares, which can result in hepatic decompensation and death. 
The U.S. FDA has explicit recommendations on managing drug induced liver injury; however, these 
recommendations do not apply to patients with underlying liver disease. Furthermore, transient 
hepatitis flares are not always harmful and may portend immune clearance of infected hepatocytes. 
Hepatitis flares may be due to direct drug-induced liver injury, drug-induced immune mediated hepatitis 
(e.g. checkpoint inhibitors), the underlying disease (incomplete viral suppression) or immune clearance 
of infected hepatocytes (successful viral suppression and accompanying restitution of the host immune 
response). The timing and course of the flare, and the associated chronological changes in serum HBV 
DNA levels can help in differentiating the cause of most but not all hepatitis flares for example flares 
related to drug-induced liver injury may by idiosyncratic and occur at any time. There was no consensus 
on definition of hepatitis flares (magnitude of ALT increase, absolute value or fold-change compared to 
baseline); however, a majority of survey respondents and the expert panel agreed that flares 
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accompanied by increase in bilirubin or prothrombin time and flares in patients with cirrhosis should be 
considered severe. Other adverse events can also occur, e.g. off-target effects of siRNA or epigenetic 
modification, autoimmunity associated with check-point inhibitors, hepatotoxicity from retention of 
dysfunctional viral particles. There was no consensus on when a trial or development of a new agent 
should be stopped due to safety concerns; however, survey respondents and the expert panel indicated 
that any death or liver transplantation, hepatic decompensation, irreversible autoimmunity, or 
incidence of severe hepatitis flare in >5% of patients could prompt a halt. Two-thirds of respondents to 
the survey and most of the expert panel recommended that safety and efficacy should be assessed for 
at least 6 months after stopping therapy.  
 
Design of clinical trials for HBV cure 
A combination of antiviral and immune modulatory therapies will most likely be needed to 
increase the likelihood of HBV cures. There was consensus that the antiviral activity and safety of 
individual new agents used as monotherapy, and infrequent or insignificant drug interactions should be 
first established before progressing to clinical trials of combination therapy.  However, demonstration of 
efficacy as a monotherapy need not be required.  
New therapies are most needed for patients at high risk of HBV-associated mortality (cirrhosis) 
and those in whom current therapies are less effective (immune tolerant, HDV infection). However, in 
designing early phase clinical trials, the target patient populations will necessarily be those who are 
most likely to respond and able to tolerate possible exacerbations of hepatitis.  The consensus was to 
initially conduct trials in treatment-naïve HBeAg-positive patients with active disease or in HBeAg-
positive or -negative patients virally suppressed on NAs.  Proof of principle and safety data would first be 
established in patients without cirrhosis.   
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A particular challenge with designing phase 2 studies is to identify a target population with 
sufficient heterogeneity to be representative of the population with chronic hepatitis B but not so 
diverse that it hinders analysis because of multiple subgroups. Among the survey respondents, 59% felt 
that patient sub-populations should be studied separately. If multiple patient populations were included 
in the same trial, patients could be potentially stratified for cirrhosis, HBeAg status, HBsAg level, HBV 
DNA level, treatment history, and HBV genotype.  Standardized criteria for ascertaining cirrhosis by non-
invasive serum markers and/or liver elastography are required.  
Given the heterogeneity of the natural course of chronic hepatitis B, there was consensus that 
randomized controlled trials are needed to establish efficacy, and comparison with placebo is feasible 
and ethical in trials for patients in the immune tolerant or inactive phases, since current guidelines do 
not recommend treatment for these patients. For patients with active disease or cirrhosis, 
investigational new agents can be compared to NA or IFN. Alternatively, the new drug can be tested 
against placebo as an additional therapy to NA. There was consensus that the trials should aim to 
demonstrate superiority of the investigational therapy.  
 
SUMMARY AND RECOMMENDATIONS  
 A summary of the recommendations on endpoints and design of clinical trials for HBV cure is 
presented in Table 2. Improved understanding of the HBV lifecycle and host immune response to HBV 
have facilitated discovery and design of antiviral therapies directed against multiple steps of the HBV 
replication cycle, as well as potential immunomodulatory therapies to restore immune response to HBV 
infection.   Development of novel HBV therapies will be further aided by the availability of improved 
cellular and animal infection models. While this progress has raised the possibility of a cure for hepatitis 
B, a complete sterilizing cure i.e. viral eradication from the host may be unrealistic due to presence of 
integrated HBV DNA. Although HBsAg clearance is infrequent, it does occur with NA and IFN therapy and 
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is associated with improved clinical outcomes. Therefore, a functional cure (characterized by sustained 
loss of HBsAg with or without anti-HBs seroconversion) after a finite course of novel antiviral and 
immune modulatory therapies in a higher proportion of patients than is currently achieved with existing 
treatments, is an attainable goal.  
Cooperation between academia, industry and regulatory agencies to standardize and validate 
surrogate markers for cure, in order to facilitate the development of curative therapies and to facilitate 
the path from discovery to regulatory approval is required.  Limited proof-of-concept monotherapy 
studies to evaluate safety and antiviral activity should be conducted prior to proceeding to combination 
therapy.  The safety of any new curative therapies will be paramount given the excellent safety of 
currently approved NAs. Continued collaboration among the stakeholders will make HBV “cure” a reality 
for patients with chronic HBV.  
 
  
Page 27 of 48
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
28 
 
Conflicts of interest:  
ASL has received research grant funding from Bristol-Myers Squibb and Gilead 
FZ has received research grants and consulting fees from Arbutus, Assembly, Gilead, Janssen, Roche, 
Sanofi 
GD has received research grants and consulting fees from Gilead Sciences, Janssen, Merck, AbbVie and 
Bristol Myers Squibb and has participated in safety monitoring boards for Regulus, Shionogi and 
Transgene.  
MGG has no conflict to declare 
 
  
Page 28 of 48
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
29 
 
Acknowledgment: 
We are deeply grateful to the governing boards of the American Association for the Study of Liver 
Diseases and the European Association for the Study of the Liver for sponsoring the HBV Treatment 
Endpoint Workshop, and all the speakers, moderators and participants for their contribution to the 
discussions. We would also like to thank the members of the Advisory Panel for their input into the 
program and survey design, and their critical review of this manuscript. The Advisory Panel members 
include:   
Debra Birnkrant MD, Eric F. Donaldson PhD, Poonam Mishra MD, MPH, Center for Drug Evaluation and 
Research, and Kathleen Whitaker PhD, Center for Devices and Radiological Health, U.S. Food and Drug 
Administration 
Timothy Block PhD, Hepatitis B Foundation and Baruch S. Blumberg Institute 
Fabrice Carrat MD, PhD, France REcherche Nord&Sud Sida-HIV Hepatites (ANRS) 
Judith Falloon PhD, MedImmune 
Lalo Flores PhD, Novira Therapeutics 
Bruce D. Given MD, Arrowhead Pharmaceuticals 
Filip Josephson MD, PhD, Swedish Medical Products Agency 
Rajen Koshy PhD, National Institute for Allergy and Infectious Diseases, National Institutes of Health 
Stephen Locarnini MD, PhD, Victorian Infectious Diseases Reference Laboratory, Melbourne 
Veronica Miller PhD, Forum for Collaborative HIV Research 
Nathalie Morgensztejn, European Medicines Agency 
Raymond Schinazi PhD, DSc, Emory University 
Averell Sherker MD, FRCPC, National Institute of Diabetes and Digestive and Kidney Diseases, National 
Institutes of Health 
G Mani Subramanian MD, PhD, Gilead Sciences  
Page 29 of 48
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
30 
 
William Symonds Pharm D, Arbutus Biopharma 
Teresa L. Wright MD, Genentech/Roche 
 
The contents of this paper represent the opinions of the authors and not necessarily the views of the 
U.S. FDA, Swedish Medical Products Agency, or European Medicines Agency.  
 
  
Page 30 of 48
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
31 
 
Figure Legends 
 
Figure 1. Phases of chronic HBV infection. 
1) Immune tolerant. HBeAg positive, high serum HBV DNA but normal ALT levels.  
2) Immune clearance/HBeAg-positive chronic hepatitis. HBeAg positive, high serum HBV DNA and 
elevated ALT levels. HBeAg seroconversion to anti-HBe occurs after varying duration.  
3) Inactive carrier. HBeAg-negative, serum HBV DNA low (generally <2000 IU/mL) or undetectable.  
4) Reactivation/HBeAg-negative chronic hepatitis. HBeAg-negative, elevated levels of HBV DNA 
and ALT in serum, HBV precore and/or basal core promoter variant often present.  
 
Traditionally phases of chronic HBV infection are defined by HBeAg status, serum HBV DNA and ALT 
levels. Quantitative HBsAg levels are different in each phase and are generally highest in immune 
tolerant phase and lowest in inactive carrier phase. While most patients progress from one phase to the 
next, not all patients go through each phase, and reversion to an earlier phase can occur.   
 
Abbreviations: ALT, alanine aminotransferase; anti-HBe, hepatitis B e antibody; HBeAg, hepatitis B e 
antigen; HBsAg, hepatitis B surface antigen 
 
Figure 2. HBV lifecycle and antiviral targets.  
1) HBV entry. Lipopeptides mimicking pre-S1 domain competing with Dane particle for binding to 
NTCP (e.g. Myrcludex B). Other small molecule inhibitors are in development. 
2) Targeting cccDNA. Prevention of cccDNA formation. Damage and destruction via cytokines or 
cccDNA sequence-specific nucleases. Functional silencing via modulation of host cellular 
epigenetic-modifying enzymes by cytokines or inhibition of viral protein function.  
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3) HBV mRNAs. small interfering RNA approaches or anti-sense oligonucleotides to block viral 
replication and viral protein expression.   
4) HBV Polymerase. Reverse transcriptase inhibitors include approved nucleos(t)ide analogues. 
RNAseH inhibitors are in preclinical evaluation. 
5) Nucleocapsid assembly and pgRNA packaging. Capsid assembly modulators can affect 
nucleocapsid assembly, pgRNA encapsidation, and may affect the nuclear functions of HBc 
(cccDNA regulation and interferon stimulated gene expression).  
6) Targeting HBsAg. Phosphorothioate oligonucleotides (NAPs) inhibiting HBsAg release and 
monoclonal antibodies to decrease circulating HBsAg load are under evaluation.  
 
Abbreviations: HBc, hepatitis B core protein; HBsAg, hepatitis B surface antigen; HBx, hepatitis B x 
protein; pgRNA, pregenomic RNA; NTCP, sodium taurocholate co-transporting polypeptide; cccDNA, 
covalently closed circular DNA.  
 
Figure 3. The immune liver microenvironment and immunotherapeutic targets 
1) Innate immune responses. IFN-α exhibits antiviral activity in infected cells, but also contributes 
to cell-mediated immunity in vivo. TLR (TLR-7 and others) agonists to boost antiviral cytokine 
production and activation of NK cells, B cells and T-cells are in clinical evaluation. Drugs 
antagonizing cIAP can sensitize HBV-infected cells to TNF-mediated apoptosis.  
2) HBV-specific T-cell exhaustion. Approaches to block inhibitory pathways (check point inhibitors: 
PD-1 blockade and others) and immunosuppressive cytokines (IL-10 and TGF-β) to achieve 
recovery of HBV-specific T cells and NK cells from chronic hepatitis B patients are currently in 
evaluation.  
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3) Engineering of redirected T cells via i) transfer of HBV-specific T-cell receptors or HBV-specific 
chimeric antigen receptors ex vivo in patient’s T cells, or ii) retargeting of immune effector cells 
towards HBV-infected cells using bispecific antibody constructs.  
4) Therapeutic vaccines. Antigenic stimulation by diverse approaches are currently being evaluated 
in phase I/II clinical trials in association with nucleos(t)ide analogues to promote CD4+ and 
CD8+T cell antiviral activity and antibody responses.  
 
Abbreviations: cIAP, cellular inhibitor of apoptosis; NK, natural killer cells; HBsAg, hepatitis B surface 
antigen; PD-1, programmed cell death protein 1; TLR, Toll-like receptor; TNF, tumor necrosis factor. 
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Table 1 Potential Diagnostic Tools/Surrogate Markers for HBV Cure 
 
HBV Marker  Purpose Rationale / comments 
HBsAg - ultrasensitive qualitative or 
quantitative assay  
To detect minimal residual HBsAg, lower limit 
of detection of Lumipulse assay 0.004 IU/mL 
compared to current assays 0.05 IU/mL  
HBsAg loss is considered the most reliable 
indicator for functional cure 
HBsAg fragments – epitope 
mapping 
To determine whether residual HBsAg is 
translated from cccDNA transcripts or 
integrated HBV DNA transcripts 
To detect antiviral-resistant / immune escape 
HBsAg variants 
Persistent detection of HBsAg may be from 
integrated HBV DNA and not cccDNA. 
Integrated HBV DNA is often fragmented 
with deletions and re-arrangements while 
cccDNA translates into full length HBsAg.  
HBsAg variants may give rise to false 
negative results or inaccuracy in 
quantification in current assays.  
Large (L) vs. Middle (M) vs. Small (S) 
surface protein  
To differentiate complete virions from empty 
envelope particles  
Complete virions are coated with L, M & S 
surface proteins but empty envelope 
particles comprise mostly S surface proteins 
HBsAg-anti-HBs immune complex To detect residual HBsAg masked by anti-HBs 
in immune complex 
HBsAg loss is considered the most reliable 
indicator for functional cure 
Quantitative HBsAg level To facilitate differentiation of inactive carriers 
from HBeAg-negative chronic hepatitis  
Serves as an intermediary measure of HBsAg 
loss 
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To predict outcome in HBeAg-negative 
patients with low serum HBV DNA 
HBsAg level declines before it becomes 
undetectable but accuracy in predicting 
HBsAg loss is low 
HBV RNA level  To predict viral relapse when treatment is 
stopped.  
 
Serves as a surrogate for transcriptionally 
active cccDNA particularly if assay is specific 
for pgRNA.  
Encapsidated pgRNA can be enveloped and 
secreted, levels higher in patients on NA 
because reverse transcription of pgRNA to 
HBV DNA is blocked. Shown in some studies 
to predict viral relapse after discontinuation 
of NA.  
Specificity of current assays for pgRNA 
versus subgenomic RNAs is unknown. 
Hepatitis B core related antigen 
(HBcrAg) 
To correlate levels with intrahepatic HBV DNA.  
To predict viral relapse when treatment is 
stopped.  
 
Translated from HBV precore/core gene, can 
assemble into defective particles that are 
secreted. Shown in some studies to correlate 
with intrahepatic HBV DNA, ccc DNA 
transcriptional activity and to predict viral 
relapse after discontinuation of NA.  
Limitation: lack of sensitivity, composite 
biomarker. 
cccDNA quantification and To quantify cccDNA from treated and cccDNA serves as template for transcription 
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transcriptional activity  untreated patients 
To assess transcriptional activity: 
pgRNA/cccDNA ratio 
of HBV RNA and translation of HBV antigens 
Most direct measure of HBV cure 
Adequate sample of liver tissue and stringent 
protocol to ensure specificity is required. 
Immune response to HBV antigens To assess role as a biomarker for treatment 
response 
Restoration of immune response is 
considered a necessary prerequisite for HBV 
cure  
Unclear what types of immune response are 
critical, what methods to use, and criteria for 
improvement or restoration of response that 
will translate to cure 
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Table 2 Summary of Recommendations on Endpoints and Design of Clinical Trials for HBV Cure 
 
Definition of functional HBV cure 
• Sustained HBsAg loss with or without anti-HBs seroconversion and undetectable HBV DNA in 
serum after completion of a finite course of treatment 
Main objective 
• To demonstrate superiority of the investigational therapy 
Control arm 
• Placebo or no treatment for patients in the immune tolerant or inactive phase 
• NA or IFN as comparator therapy or add-on therapy to investigational therapy for patients with 
active disease or cirrhosis (IFN as comparator only if no cirrhosis or compensated cirrhosis with 
no portal hypertension) 
Patient profile for initial trials  
• HBeAg-positive patients with active disease, not currently on treatment 
• HBeAg-positive or HBeAg-negative patients with baseline active liver disease, who are virally 
suppressed on NAs 
• Factors to consider for stratification 
o HBeAg status 
o HBsAg level 
o Cirrhosis  
o HBV DNA level 
o Treatment history 
o HBV genotype 
Primary efficacy endpoint 
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• Phase 2 trials: Suppression of HBV DNA in serum to undetectable month 6 on-treatment or 
month 6 post-treatment, decline in serum HBsAg level may be used as exploratory endpoint in 
trials enrolling patients virally suppressed on NAs and in trials of compounds targeting HBsAg 
• Phase 3 trials: HBsAg and HBV DNA not detectable in serum month 6 post-treatment, must 
include long-term follow-up to confirm durability of response after completion of treatment 
Safety issues 
• Evidence of safety of new drugs as monotherapy, and evaluation of infrequent or insignificant 
drug interactions needed before new drugs are combined 
• Hepatitis flares: need to differentiate flares due to immune clearance versus other causes 
• Severe flares: hepatitis flares accompanied by increase in bilirubin or prothrombin time or 
occurring in patients with cirrhosis  
• Any adverse event leading to death or liver transplantation, hepatic decompensation, 
irreversible autoimmunity, or incidence of severe hepatitis flare in >5% patients may prompt 
consideration for stopping trial 
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Figure 1. Phases of chronic HBV infection  
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Figure 2. HBV lifecycle and antiviral targets.  
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Figure 3. The immune liver microenvironment and immunotherapeutic targets  
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e Targets Compounds Developer Stage of 
development 
ClinicalTrials.gov identifier 
 
 
 
 
Direct 
acting 
antivirals 
HBpol GS-7340; Tenofovir 
Alafenamide Fumarate 
(prodrug of tenofovir) 
Gilead Approved NCT01940471 and NCT01940341 
HBpol AGX-1009 
(prodrug of tenofovir) 
Agenix/ Cinkate 
Pharmaceutical 
 
Phase 3 No identifier found 
HBpol LB80380; Besifovir IlDong Pharmaceutical Phase 3 NCT01937806 
HBpol CMX-157  
(prodrug of tenofovir) 
Contravir Phase 2a NCT02710604 
HBc GLS-4 
(Morphothiadine mesilate) 
HEC Pharm/SUnshine Phase 2 China-CFDA 
HBc 
 
HBc 
 
 
HBc 
NVR 3-778 
 
 
JNJ56136379 
 
Core protein Allosteric 
Modifier (CpAM) 
Novira 
Pharmaceuticals/JnJ 
 
JnJ Janssen 
 
 
Assembly Biosciences 
Phase 1a 
 
 
Phase 1 
 
 
Phase 1 
NCT02112799 & NCT02401737 
 
 
NCT02662712 
 
 
 
 
HBs REP-2139 & 2165 
(Nucleic acid polymers) 
Replicor Phase 2 for both HBV 
and HDV 
NCT02565719 and NCT02233075 
Unknown RG7834 Roche Phase I New Zealand 
Viral RNAs siRNA: ARC-520/ARC-521 
 
ALNHBV 
 
ARB-1467 
 
Lunar HBV 
 
BB HB 331 
Arrowhead 
 
Alnylam 
 
Arbutus 
 
Arcturus /Janssen 
 
Benitec 
Discontinued 
 
Phase 1/2 
 
Phase 2 
 
Preclinical 
 
Preclinical 
NCT02604212 and NCT02604199 
 
NCT02826018 
 
NCT02631096 
Viral RNAs siRNA: Ionis HBVRx Ionis 
pharmaceuticals/GSK 
Phase 1  
 
 
 
 
 
NTCP Myrcludex Hepatera Phase 2 for both HBV 
and HDV 
NCT02881008/NCT02637999 
Promotion of apoptosis 
in infected cells 
Birinapant Tetralogic Phase 1 NCT02288208 
Prenylation/farnesylation Lonafarnib Eiger 
BioPharmaceuticals 
Phase 2 for HDV NCT02430181, NCT02430194, 
NCT02511431 
Immune stimulation Thymosin alpha Seoul National Phase 4 NCT00291616 
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Host 
targeting 
agents 
University Hospital 
Cyclophilins CPI431 Contravir/ Ciclofilin 
Pharmaceuticals 
preclinical  
Cyclophilins NVP018 Neurovive/ OnCore 
Biopharma 
preclinical  
pDC stimulation GS-9620 (TLR7 agonist) Gilead Phase 2 NCT02579382 
Immune stimulation INO-1800 (therapeutic 
vaccine) 
Inovio Pharmaceuticals Phase 1 NCT02431312 
Immune stimulation Cyt-107 (IL-7) Cythesis Phase 1/2 
(discontinued) 
NCT01027065 
Immune stimulation SB9200 SpringBank Phase 2 NCT 02751996 
Immune stimulation IFN-lambda BMS Phase 2 (discontinued) NCT01204762 
Adaptive responses ABX-203 Abivax Phase 2/3 NCT02249988 
Adaptive responses CVI-HBV-002 (S) CHA Vaccine Institute  Phase 1/2 NCT02693652 
Adaptive responses Engerix-B + NA Chang Gung Memorial 
Hospital 
Phase 4 NCT02505009 
NCT01817725 
Adaptive responses Euvax B (S) + PEG IFN + 
ETV 
Seoul National 
University 
Phase 4 CT02097004 
Adaptive responses Nivolumab (Anti-PD1 mAb) Ono 
Pharmaceuticals/BMS 
Phase 1/2  for HCC NCT01658878 
 
Adaptive responses pPDPSC18 Powder Med  NCT00277576 
Adaptive responses IFN + IL2 + HepB vaccine Tongji Hospital  NCT02360592 
Adaptive responses HBsAg-activated MoDC Sun Yat-Sen University  NCT01935635 
Therapeutic DNA 
vaccine 
HB110 Ichor/Janssen Phase 1  
(completed) 
NCT01641536 
Therapeutic vaccine Tomegavax HBV  TomegaVax Phase 1  
Therapeutic vaccine HepTcell  
 
FP-02.2 (Peptide vaccine) 
Altimmune Phase 1 
 
Phase 1 
UK 
 
NCT02496897 
Therapeutic vaccine GS-4774  Gilead Phase 2 NCT02174276 
Therapeutic vaccine TG-1050  Transgene Phase 1 NCT02428400 
Therapeutic vaccine DV-601 (S and C)  Dynavax Phase 1 Completed 
Therapeutic vaccine HB-110E Genexine Phase 1 NCT01641536 
Unknown RG7795 (ANA773) Roche Phase 2  
Unknown RO6864018 Roche Phase 2 NCT02391805 
      
	
NA: nucleos(t)ide analogue; PEG IFN: pegylated interferon; TLR: toll-like receptor 
 
Supplementary Table 1: List of HBV antiviral and immune modulatory therapies in clinical trials 
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